MRA Advisory Group Buys New Position in Elanco Animal Health Incorporated $ELAN

MRA Advisory Group bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 31,512 shares of the company’s stock, valued at approximately $776,000.

Other institutional investors have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Elanco Animal Health during the 1st quarter worth approximately $2,065,000. Goldman Sachs Group Inc. lifted its position in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares during the period. Empowered Funds LLC boosted its stake in Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Elanco Animal Health by 4.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after acquiring an additional 76,408 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Elanco Animal Health by 2,006.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after purchasing an additional 295,651 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the purchase, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is owned by insiders.

Elanco Animal Health Stock Down 8.9%

ELAN stock opened at $22.06 on Friday. The firm has a market capitalization of $11.02 billion, a PE ratio of -53.80, a P/E/G ratio of 1.45 and a beta of 1.67. The company has a quick ratio of 1.12, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a twelve month low of $16.15 and a twelve month high of $27.98. The stock’s 50 day moving average is $24.70 and its 200-day moving average is $24.09.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.Elanco Animal Health’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on ELAN shares. UBS Group lifted their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday. TD Cowen boosted their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Citigroup upped their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, KeyCorp increased their price target on Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus price target of $29.09.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.